Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression

Leukemia

Volumn 30, Issue 1, 2016, Pages 124-130

  Mayado, A ^a   Teodosio, C ^b   Garcia Montero, A C ^a   Matito, A ^c   Rodriguez Caballero, A ^a   Morgado, J M ^c   Muniz C ^a,d   Jara Acevedo, M ^a   Alvarez Twose I ^c   Sanchez Munoz L ^c   Matarraz, S ^a   Caldas, C ^a   Munoz Gonzalez, J I ^a   Escribano, L ^a   Orfao, A ^a  

^a Centro de Investigacion del Cancer   (Spain)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c HOSPITAL VIRGEN DE LA SALUD   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLUSTERIN; CYTOKINE; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; PROTEIN CCL23; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; BETA CHEMOKINE; CCL23 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN;

ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; INDOLENT SYSTEMIC MASTOCYTOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; GENETICS; IMMUNOLOGY; MORTALITY; MUTATION; RISK; SYSTEMIC MASTOCYTOSIS;

CHEMOKINES, CC; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MASTOCYTOSIS, SYSTEMIC; MUTATION; PROTO-ONCOGENE PROTEINS C-KIT; RISK;

EID: 84953371082     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.176     Document Type: Article

References (32)

1. Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: a review. Histopathology 1979; 3: 349-365.
2. Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004; 114: 3-11, quiz 2.
3. Metcalfe DD. The liver, spleen, and lymph nodes in mastocytosis. J Invest Dermatol 1991; 96: 45S-46S.
4. Horny HP, Metcalfe DD, Bennet JM, Bain BJ, Akin C, Escribano L et al. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds). World Health Organization (WHO) Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer (IARC): Lyon, 2008; pp 54-63.
5. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366-2372.
6. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007; 138: 12-30.
7. Akin C, Metcalfe DD. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 2004; 114: 13-19, quiz 20.
8. Alvarez-Twose I, Jara-Acevedo M, Morgado JM, Garciá-Montero AC, Sánchez-Munõz L, Teodósio C et al. Clinical, immunophenotypical and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol 2015; e-pub ahead of print 19 June 2015; doi:10.1016/j.jaci.2015.05.008.
9. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009; 113: 5727-5736.
10. Escribano L, Alvarez-Twose I, Sanchez-Munoz L, Garcia-Montero A, Nunez R, Almeida J et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009; 124: 514-521.
11. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, Alvarez-Twose I, Sanchez-Munoz L, Almeida J et al. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis. Leukemia 2012; 26: 951-958.
12. Jara-Acevedo M, Teodósio C, Sánchez-Munõz L, Alvarez-Twose I, Mayado A, Caldas C et al. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. Mod Pathol 2015; 28: 1138-1149.
13. Matito A, Morgado JM, Alvarez-Twose I, Sanchez-Munoz L, Pedreira CE, Jara-Acevedo M et al. Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome. PLoS One 2013; 8: e76116.
14. Brockow K, Akin C, Huber M, Metcalfe DD. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 2005; 115: 216-223.
15. Nedoszytko B, Niedoszytko M, Lange M, van Doormaal J, Glen J, Zablotna M et al. Interleukin-13 promoter gene polymorphism-1112C/T is associated with the systemic form of mastocytosis. Allergy 2009; 64: 287-294.
16. Hartmann K, Wagner N, Rabenhorst A, Pflanz L, Leja S, Forster A et al. Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients. J Allergy Clin Immunol 2013; 132: 232-235.
17. Adams DH, Lloyd AR. Chemokines: leucocyte recruitment and activation cytokines. Lancet 1997; 349: 490-495.
18. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, Sanchez-Munoz L, Pedreira CE, Alvarez-Twose I et al. Gene expression profile of highly purified bone marrow mast cells in systemic mastocytosis. J Allergy Clin Immunol 2013; 131: 1213-1224, e1-4.
19. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603-625.
20. Horny HP, Sotlar K, Valent P, Hartmann K. Mastocytosis: a disease of the hematopoietic stem cell. Dtsch Arztebl Int 2008; 105: 686-692.
21. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435-453.
22. Rodriguez-Caballero A, Garcia-Montero AC, Bueno C, Almeida J, Varro R, Chen R et al. A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation. Lab Invest 2004; 84: 1387-1398.
23. Rueff F, Przybilla B, Bilo MB, Muller U, Scheipl F, Aberer W et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124: 1047-1054.
24. Akin C, Valent P. Diagnostic criteria and classification of mastocytosis in 2014. Immunol Allergy Clin North Am 2014; 34: 207-218.
25. Akin C, Schwartz LB, Kitoh T, Obayashi H, Worobec AS, Scott LM et al. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology. Blood 2000; 96: 1267-1273.
26. Pardanani A, Finke C, Abdelrahman RA, Lasho TL, Hanson CA, Tefferi A. Increased circulating IL-2Ralpha (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine-phenotype study. Leukemia 2013; 27: 1430-1433.
27. Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2002; 128: 344-350.
28. Rabenhorst A, Christopeit B, Leja S, Gerbaulet A, Kleiner S, Forster A et al. Serumlevels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis. J Allergy Clin Immunol 2013; 132: 1234-7 e7.
29. Nardelli B, Tiffany HL, Bong GW, Yourey PA, Morahan DK, Li Y et al. Characterization of the signal transduction pathway activated in human monocytes and dendritic cells by MPIF-1, a specific ligand for CC chemokine receptor 1. J Immunol 1999; 162: 435-444.
30. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010; 10: 89-102.
31. Essabbani A, Garcia L, Zonetti MJ, Fisco T, Pucci S, Chiocchia G. Exon-skipping strategy by ratio modulation between cytoprotective versus pro-apoptotic clusterin forms increased sensitivity of LNCaP to cell death. PLoS One 2013; 8: e54920.
32. Trougakos IP, Djeu JY, Gonos ES, Boothman DA. Advances and challenges in basic and translational research on clusterin. Cancer Res 2009; 69: 403-406.